Rackspace Has Been Moving

May 13, 2026

Rackspace Has Been Moving

The AMD deal, the short squeeze, and the balance sheet reality traders can’t ignore.


The Quick Version

  • RXT surged 55% on May 7 after a Q1 revenue beat and an AMD Enterprise AI Cloud agreement
  • Stock ran from ~$1.40 to an intraday high of $6.72 in under two weeks
  • Q1 revenue: $678M (+2% YoY), public cloud up 7%, private cloud down 6%
  • GAAP net income flipped positive but included a $55.8M one-time debt gain — underlying recovery is modest
  • The AMD deal is non-binding. No contracted revenue, no rollout timeline, not in 2026 guidance
  • $3.05B in long-term debt against $93.6M in cash. Debt matures mid-2028
  • Analyst consensus target: $2.17. Stock is trading near $5.00
  • Next hard catalyst: Q2 earnings August 6

Rackspace Technology (NASDAQ: RXT) spent most of late April doing nothing. Grinding between $1.40 and $1.80, ignored by most desks, sitting on a balance sheet that would make most credit analysts flinch. Then May 7 arrived.

The stock jumped 55% on earnings day alone, closing at $3.52. It kept moving. By May 12, RXT tagged an intraday high of $6.72. From a late-April low of $1.40, that’s a multi-bagger compressed into less than two weeks. The 52-week low was $0.393. One of the more violent reversals in small-cap cloud in recent memory.

Two things collided: a Q1 earnings beat and an AMD agreement that gave buyers something to act on. Whether that holds up is the more interesting question.

Sponsored

The Opportunity Often Comes Before the Listing

Med-X is preparing for a potential Nasdaq listing under the reserved ticker MXRX, giving early investors an opportunity to invest before broader public market exposure.

The company has already generated millions in sales, operates across 41 markets, carries zero long-term debt, is backed by Maxim Group Investment Bank, and has retail distribution through Amazon, Walmart, and Kroger.

As demand continues to grow for safer, plant-based pest control solutions, Med-X is positioning itself within the rapidly expanding $17.6B biopesticide market.

Explore Med-X and become a shareholder at $4/share ahead of its planned Nasdaq listing

Disclosures: This is a paid advertisement for Med-X’s Regulation A+ Offering. Please read the offering circular at invest.medx-rx.com.

On the numbers: Q1 revenue hit $678M, up 2% YoY, edging past the $674.95M Street estimate. Public cloud grew 7% to $443M. Private cloud slipped 6% to $235M, which management blamed on healthcare onboarding timing. Non-GAAP operating profit climbed 20% to $31M. GAAP net income flipped to $8.3M, but that figure included a $55.8M one-time gain on debt extinguishment. Strip that out and the recovery looks more modest. Non-GAAP EPS came in at -$0.06, missing the -$0.03 consensus. Gross margins also contracted year-over-year. Adjusted EBITDA was $71.2M for the quarter, but pretax margins are still roughly -21%.

On the AMD deal: Rackspace and AMD signed a multiyear MOU to co-build a governed Enterprise AI Cloud targeting regulated industries — healthcare, financial services, government — where handing workloads to a hyperscaler and walking away isn’t an option. AMD Instinct GPUs and EPYC CPUs would power the stack, with Rackspace owning full operational accountability. CEO Gajen Kandiah called it a solution to a real and largely unaddressed market gap. CFO Mark Marino confirmed on the call that AMD revenue is not in 2026 guidance due to supply chain and delivery timing. Management’s own framing puts this as a 2027-and-beyond opportunity. That’s worth sitting with — the stock doubled off a deal that won’t generate material revenue for at least 18 months.

Slight tangent: the Palantir partnership closed its first joint deal in 41 days during the quarter, cutting a solar manufacturer’s quoting cycle by 94% using Palantir Foundry. The deal expanded into EMEA shortly after. One data point, not a trend, but it’s the right kind of data point.

Full-year 2026 guidance was left unchanged despite the stock tripling: revenue $2.6 to $2.7B, adjusted EBITDA $305 to $315M. Management didn’t revise a single line after the biggest announcement in years. BMO raised its target to $5.00 with an Outperform. RBC held at $2.50. Consensus sits at $2.17 across three analysts. The stock is near $5.00.

Sponsored

If your friend is talking about SpaceX, that’s GREAT NEWS…

Right now, the world is laser-focused on the SpaceX IPO – and that’s GREAT NEWS for you…

Because Matt Monaco believes the SpaceX IPO is chump change compared to ‘Elon’s iPhone’.

Matt turned $2,000 into $3 million by spotting the crypto and AI mega trends early…

But he predicts ‘Elon’s iPhone’ could unleash the biggest mega trend in HISTORY (and it could happen as soon as July 22nd)

Click here to see why >

On squeeze day, over 60 million shares changed hands, more than triple the 20-day average. Shorts caught heavily positioned into a binary catalyst got squeezed hard. The AI angle gave buyers a reason to press the move. That combination doesn’t last forever, but it can run longer than logic suggests it should.


Trading Cheat Sheet

  • Bull case ($7 to $8): AMD MOU converts to a binding contract with 2027 revenue visibility, private cloud stabilizes as healthcare onboarding clears, Palantir pipeline scales into real bookings
  • Base case ($3.50 to $5.50): No new contracts, volume normalizes, stock grinds sideways into Q2 earnings on August 6 — AMD remains an option on future execution, not a current driver
  • Bear case (back toward $2): MOU stalls or gets restructured, private cloud declines persist beyond management’s timing explanation, $3B+ debt load returns to focus
  • Support zone ($3.50 to $3.80): Where the original surge ignited — dip-buyers have shown up here on pullbacks
  • Resistance zone ($5.00 to $5.50): Profit-taking has been visible in this range — needs sustained volume to push through
  • Breakout level ($6.72): Intraday high from May 12 — this is the level to watch for continuation
  • Next catalyst: Q2 earnings August 6, any AMD contract announcement, or a guidance revision before then

Watch volume on any pullback. Declining volume holding above $3.50 is a very different read than a high-volume flush through it. Position sizing relative to the daily range is not optional — this stock has moved 20% or more in a single session multiple times in the past two weeks.

The AMD deal either becomes a contract or it doesn’t. Management either revises guidance in August or they don’t. Everything else is noise until one of those things changes.

Sponsored

Your Download Link (Expiring)

If you still haven’t downloaded the free Simple Options Trading For Beginners guide…

…please take a few seconds and download it right now before your download link expires.

I eventually plan to charge money for this report, so do yourself a favor and download it now…

That way, no matter what it costs in the future, you’ll have a free copy on your computer.

Make sense?

Simple Options Trading For Beginners (Download Link Expires)


For informational and educational purposes only. Not investment advice. Trading involves risk, including loss of principal.

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Recent Posts

Categories